Allergan, Inc.—a global, multispecialty healthcare company headquartered in
Irvine, California—discovers, develops, and commercializes innovative pharmaceuticals, biologics, and medical devices that enable people to live life to its greatest potential—to see more clearly, move more freely, and express themselves more fully. Allergan is focused on bringing innovative products to the specialty markets of ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention, and urologics. Founded in 1950 as a private company and publicly held since 1970, Allergan now has worldwide revenues of over $3 billion, has more than 7500 employees, and operates state-of-the-art research and development (R&D) facilities and world-class manufacturing plants.

With sales and marketing capabilities in more than 100 countries, Allergan is a global presence as well as a global market leader in eye care. Allergan Eye Care is committed to discovering and developing new therapeutic agents in the areas of optic nerve function, corneal health, and retinal function—with our sights set on a promising future.

Allergan is dedicated to new drug discovery. The depth of Allergan’s commitment to R&D is confirmed by more than 1300 scientists and allied research personnel who work to develop innovative new products. Allergan’s strong internal R&D capabilities, combined with extensive industry and academic collaborations, have led to a robust, new product-development program. Allergan has entered into strategic industry partnerships in the areas of glaucoma, dry eye, age-related macular degeneration (AMD), and other retinal diseases.

Allergan has a history of innovative firsts in ophthalmology medicine, including the first ophthalmic steroid/decongestant, the first ophthalmic vasoconstrictor, the first nonsteroidal ocular anti-inflammatory, the first prostamide for the treatment of elevated intraocular pressure (IOP) and ocular hypertension, the first ophthalmic alpha-2 agonist, and the first and only prescription eye drop for increasing tear production.
Allergan is a recognized leader in corneal health, offering advanced treatments for diseases that compromise the ocular surface—such as dry eye, ocular infection, and ocular inflammation. Allergan’s portfolio of leading products includes steroidal and nonsteroidal anti-inflammatory agents, plus a comprehensive line of artificial tears.

Our fourth-generation fluoroquinolone represents a major advancement in
counteracting emerging pathogens due to its broad-spectrum activity and optimal formulation. Allergan has expanded treatment for dry eye with the only prescription eye drop for increasing tear production—the first drug to treat an underlying cause of chronic dry eye.

To protect optic nerve function, Allergan has the most comprehensive portfolio of IOP-lowering therapies of any eye care company. Ongoing research efforts are focused on revolutionary new treatments, independent of IOP lowering. These treatments have the potential to prevent the progression of visual impairment by targeting common pathways of cell injury.

For the treatment of retinal diseases, Allergan is directing considerable R&D efforts toward novel approaches. Allergan’s retinal research program is multifaceted, encompassing varying retinal diseases and therapeutics. Pharmacologic alternatives include antiangiogenesis with tyrosine kinase inhibitors and siRNA technology, as well as corticosteroids, retinoids, N-methyl-D-aspartate (NMDA) receptor antagonists, and alpha agonists. Other research efforts are also focused on a novel drug delivery system.

Allergan is committed to the concept of “No Limits in Sight” for patients around the world.

Disclaimer
The material published electronically is for information purposes only. Allergan Inc. and its affiliates (collectively referred to as “Allergan”) do not guarantee that the information is complete or correct. Allergan do not accept any responsibility for loss or damage suffered by any person or body relying directly or indirectly on any of the information provided.
This site may contain third party advertisements and links to third party sites. Allergan do not make any representation as to the accuracy or suitability of any of the information contained in those advertisements or sites and do not accept any responsibility or liability for the conduct or content of those advertisements and sites and the offerings made by the third parties.
Third party advertisements and links to other sites where goods or services are advertised are not endorsements or recommendations by Allergan of the third party sites, goods or services. Access to or use of them is at your own risk.